Delix Therapeutics

An amazing time was had by all at the Delix Summer Porchfest 2024, featuring our very own “house band,” the Neuroplastic Fantastic! It’s always important to come together, relax, and enjoy some well-deserved time with our team and families. A big thank you to all Delix Therapeutics team members who made it such a memorable day! We wish everyone a great rest of the summer filled with memorable moments with your own families and friends.

Today we observe #WorldBrainDay, dedicated to promoting #brainhealth and raising awareness about neurological disorders. With over 3 billion people affected by #neurological conditions worldwide, advancing brain research is crucial for improving cognitive function, reducing the risk of neurological issues, and enhancing overall #mentalhealth. At Delix Therapeutics, we're leveraging the brain's natural capacity for targeted restoration and repair. Our innovative compounds hold the potential to revolutionize the treatment landscape for various #CNS conditions. Learn more about our innovative #neuroplastogens here: https://lnkd.in/dqnHGFyw.

Meet Rajiv Agrawal, Associate Director, Pharmacology at Delix Therapeutics! Rajiv pushes the boundaries of #CNS drug discovery by tackling new challenges and contributing to essential research projects. His expertise is invaluable as we continue to strive to develop innovative therapeutics for patients with #neuropsychiatric conditions. 

We’re excited to welcome Sydney DeCaro to #TeamDelix as a Clinical Trial Associate. Sydney shared her reasons for joining #TeamDelix: “I am very excited to join the Delix Therapeutics team! Having worked on an intravenous ketamine trial for severe depression, I witnessed firsthand the remarkable effect of plastogens in those suffering from neuropsychiatric disorders. However, I also recognized the challenges related to accessibility, scalability, and the substantial resources and time required for administration and monitoring. Delix’s lead compound has the potential to overcome these challenges and reach a much broader patient population, which fueled my interest in joining the team. I am thrilled to be joining the innovative and driven team at Delix!” We’re excited to have Sydney on board and know her expertise will be a significant asset to the team.

On #NationalPTSDAwarenessDay, we raise awareness of the daily struggles faced by millions impacted by post-traumatic stress disorder. Delix Therapeutics recognizes the profound impact PTSD has on patients and their loved ones, which is why our research is at the forefront of understanding the neurological mechanisms underlying this disease. Through our novel #neuroplastogen development platform, we're committed to pursuing transformative treatment options for patients with debilitating #neuropsychiatric disorders. Learn more about our approach here: https://lnkd.in/eCRnJMv5.

Scientific American recently published a piece highlighting the potential of next-generation psychedelics as medicines, especially non-hallucinogenic compounds like Delix Therapeutics's #neuroplastogens. The article features our CSO Kurt Rasmussen and our CMO Aaron Koenig MD discussing our groundbreaking work with our lead #neuroplastogen, DLX-001, and how Delix is pioneering innovative new treatments for #neuropsychiatric conditions that deliver therapeutic benefits without causing hallucinogenic or cardiotoxic effects. Check out the full article: https://lnkd.in/eaWzGF7h.

In a recent article, POLITICO highlighted the United States Department of Defense grant awarded to Delix Therapeutics to support the ongoing development of our novel, non-hallucinogenic #neuroplastogen designed to safely repair and restore hearing loss for both military personnel and civilians. Read the full piece here: https://lnkd.in/gBNWBGAw.

June is #AlzheimersandBrainAwarenessMonth, an important time to raise awareness of the significance of #brainhealth.  At Delix Therapeutics, we're developing first-in-class #neuroplastogens that promote the brain's innate ability to repair itself, and in doing so, pioneering a new era in #CNS disease treatment. Learn more about our science here: https://lnkd.in/eCRnJMv5.

In a recent article by The Guardian, David E. Olson, our Chief Innovation Officer, discusses the effectiveness of psychedelic drugs in treating #neuropsychiatric conditions like depression, PTSD, and substance abuse disorders. Additionally, he underlines Delix Therapeutics' innovative approach for developing therapies that move beyond traditional psychedelics and promote rapid and enduring neuronal growth without inducing hallucinogenic effects. Check out the full story: https://lnkd.in/ei3iFR9x. 

#TeamDelix was proud to be a sponsor of NAMI Massachusetts annual walk in Boston, an opportunity to stand alongside an organization dedicated to providing a wide range of resources for individuals and families navigating #mentalhealth conditions. It was an incredible event and we’re thrilled to have been a part of it! #IOOV